Cybin (HELP) Short-term Investments (2022 - 2023)
Cybin (HELP) reported Short-term Investments of $1.9 million for Q1 2023, up 194.31% on a YoY basis from $629981.1 in Q1 2022, and up 194.31% quarter-over-quarter from -$2.0 million in Q1 2022.
Cybin (HELP) Short-term Investments (2022 - 2023) Analysis & Trends
Cybin has reported Short-term Investments for 2 years, with the latest figure at $1.9 million in Q1 2023.
- For the quarter ending Q1 2023, Short-term Investments rose 194.31% year-over-year to $1.9 million; the trailing twelve-month figure through Feb 2023 stood at $1.9 million (up 194.31% YoY), and the FY2023 full-year result was $1.9 million, up 195.46% from the prior year.
- Short-term Investments for Q1 2023 stood at $1.9 million, up from -$2.0 million in the prior quarter.
- The five-year high for Short-term Investments was $1.9 million in Q1 2023, with the low at -$2.0 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Cybin | 75.42 Mn | 75.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2023 | 1.85 Mn |
| Feb 28, 2022 | -1.97 Mn |